Arcellx saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 73 to 83.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.
Arcellx is not currently near a potential buy zone. See if the stock goes on to build a base that could ignite a new run.
Arcellx reported 0% earnings growth in its most recent report, while sales growth came in at -79%. The next quarterly results are expected on or around Aug. 18.
Arcellx earns the No. 287 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
